Biomarker for Krabbe Disease (BioKrabbe)

CENTOGENE GmbH Rostock

Overview

Development of a new MS-based biomarker for the early and sensitive diagnosis of Krabbe Disease from blood

Krabbe disease is a rare, hereditary degenerative disorder of the central and peripheral nervous systems. It is characterized by the presence of globoid cells (cells that have more than one nucleus), the breakdown of the nerve's protective myelin coating, and destruction of brain cells. Krabbe disease is one of a group of genetic disorders called the leukodystrophies. These disorders impair the growth or development of the myelin sheath, the fatty covering that acts as an insulator around nerve fibers, and cause severe deterioration of mental and motor skills. Myelin is a complex substance made up of at least 10 different enzymes. Each of the leukodystrophies affects one (and only one) of these substances. Krabbe disease is caused by a deficiency of galactocerebrosidase, an essential enzyme for myelin metabolism. The disease most often affects infants, with on-set before age 6 months, but can occur in adolescence or adulthood. Symptoms include irritability, unexplained fever, limb stiffness, seizures, feeding difficulties, vomiting, and slowing of mental and motor development. Other symptoms include muscle weakness, spasticity, deafness, and blindness. Overall calculated European frequency is 1 case per 100,000 populations, with a higher reported incidence in Sweden of 1.9 cases per 100,000 populations. An unusually high incidence, 6 cases per 1000 live births, is reported in the Druze community in Israel. New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma) of affected patents specific metabolic alterations that allow to diagnose in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to develop new biochemical markers from the plasma of the affected patients helping to benefit the patient by an early diagnose and thereby with an earlier treatment.

Study Type

OBSERVATIONAL

Conditions

Krabbe Disease

Eligibility

Sex: ALLMin age: 1 Year

Medical Language ↔ Plain English

INCLUSION CRITERIA: * Informed consent will be obtained from the patient or the parents before any study related procedures. * Patients of both gender from one year old * The patient has a diagnosis of Krabbe Disease EXCLUSION CRITERIA: * No Informed consent from the patient or the parents before any study related procedures. * Patients younger than one year * The patient has no diagnosis of Krabbe Disease

Locations (5)

Children's Hospital, Faculty of Medicine, Ain Shams University

Cairo, Egypt

Centogene AG

Rostock, Germany

Amrita Institute of Medical Sciences

Kerala, India

Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)

Mumbai, India

Outcomes

Primary Outcomes

Development of a new MS-based biomarker for the early and sensitive diagnosis of Krabbe disease from plasma

New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

Time frame: 24 month

Secondary Outcomes

Testing for clinical robustness, specificity and long-term stability of the biomarker

the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.